ArticleIn vivo (Athens, Greece)
Association of
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe incidence of thyroid cancer has increased predominantly due to an increase in papillary thyroid cancer (PTC). Alteration of toll-like receptor function has been reported to play a crucial role in carcinogenesis. The aim of the present study was to investigate predisposition to PTC associated with genetic markers of toll-like receptor and interleukin-1 receptor pathways involving nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-ĸB) stimulation. Specifically, the study focused on the following genes: interleukin-1 receptor-associated kinase 1 (IRAK1, rs3027898), NF-ĸB inhibitor alpha (NFKBIA, rs696), NF-ĸB subunit 1 (NFKB1, rs28362491), and microRNA-146a (miR-146a, rs2910164). PATIENTS AND
methodsForty-eight unrelated patients with papillary cancer restricted to the thyroid gland and 93 healthy volunteers were enrolled in the study.
resultsA strong statistically significant difference was observed between patients with PTC and controls for IRAK1 rs3027898 variant. When the statistical analysis was replicated taking into account patient's sex, the rs3027898 A allele was revealed to be the risky variant in males.
conclusionAdditional studies in larger groups of patients of various origins are needed to validate these preliminary findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.